Ocular manifestations of systemic lupus erythematosus: a review of the literature

Neal V Palejwala, Harpreet S Walia, Steven Yeh, Neal V Palejwala, Harpreet S Walia, Steven Yeh

Abstract

About one-third of patients suffering from systemic lupus erythematosus have ocular manifestations. The most common manifestation is keratoconjunctivitis sicca. The most vision threatening are retinal vasculitis and optic neuritis/neuropathy. Prompt diagnosis and treatment of eye disease is paramount as they are often associated with high levels of systemic inflammation and end-organ damage. Initial management with high-dose oral or IV corticosteroids is often necessary. Multiple "steroid-sparing" treatment options exist with the most recently studied being biologic agents.

Figures

Figure 1
Figure 1
Slit-lamp photo demonstrating diffuse anterior scleritis in a patient with SLE.
Figure 2
Figure 2
Fundus photograph demonstrating severe retinal vasculitis. Significant ischemia is present which is highlighted by the attenuated and sclerotic vasculature. Panretinal photocoagulation was required to treat ischemic and neovascular complications.
Figure 3
Figure 3
(a) Macular serous retinal detachment in a patient with lupus choroidopathy. (b) Multiple areas of hyperfluorescence seen on fluorescein angiography caused by increased vascular permeability of the choroidal circulation. (c) Large accumulation of subretinal fluid is seen on optical coherence tomography.

References

    1. Tikly M, Navarra SV. Lupus in the developing world—is it any different? Best Practice and Research. 2008;22(4):643–655.
    1. D’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. The Lancet. 2007;369(9561):587–596.
    1. Sullivan KE. Genetics of systemic lupus erythematosus: clinical implications. Rheumatic Disease Clinics of North America. 2000;26(2):229–256.
    1. Walport MJ, Black CM, Batchelor JR. The immunogenetics of SLE. Clinics in Rheumatic Diseases. 1982;8(1):3–21.
    1. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Research. 2002;4(supplement 3):S279–S293.
    1. Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. Journal of Experimental Medicine. 1967;126(4):607–624.
    1. Berden JHM, Licht R, Van Bruggen MCJ, Tax WJM. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Current Opinion in Nephrology and Hypertension. 1999;8(3):299–306.
    1. Michaud JL, Lemieux LI, Dubé M, Vanderhyden BC, Robertson SJ, Kennedy CRJ. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant α-actinin-4. Journal of the American Society of Nephrology. 2003;14(5):1200–1211.
    1. Rubin R. Drug induced lupus. In: Wallace BH, Hahn DJ, editors. Dubois’ Lupus Erythematosus. 6th edition. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2002. pp. 885–916.
    1. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Annals of Internal Medicine. 2005;142(12 I)
    1. Stavrou P, Murray PI, Batta K, Gordon C. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. British Journal of Ophthalmology. 2002;86(4):474–475.
    1. Grimson BS, Simons KB. Orbital inflammation, myositis, and systemic lupus erythematosus. Archives of Ophthalmology. 1983;101(5):736–738.
    1. Serop S, Vianna RNG, Claeys M, De Laey JJ. Orbital myositis secondary to systemic lupus erythematosus. Acta Ophthalmologica. 1994;72(4):520–523.
    1. Arnold HL., Jr Lupus erythematosus profundus, commentary and report of four more cases. Archives of Dermatology. 1956;73(1):15–33.
    1. García-Díez A, Fraga J. Lupus erythematosus panniculitis. Dermatologic Clinics. 2008;26(4):453–463.
    1. Jordan DR, McDonald H, Olberg B, McKim D, McKendry R. Orbital panniculitis as the initial manifestation of systemic lupus erythematosus. Ophthalmic Plastic and Reconstructive Surgery. 1993;9(1):71–75.
    1. Feinfield RE, Hesse RJ, Rosenberg SA. Orbital inflammatory disease associated with systemic lupus erythematosus. Southern Medical Journal. 1991;84(1):98–99.
    1. Siebert S, Srinivasan U. Proptosis can be the presenting feature of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2004;63(8):908–909.
    1. Arthurs BP, Khalil MK, Chagnon F, Lindley SK, Anderson DP, Burnier M. Orbital infarction and melting in a patient with systemic lupus erythematosus. Ophthalmology. 1999;106(12):2387–2390.
    1. Kao TY, Yoon MK, McCulley TJ, Ruben BS, Hwang TN. Acquired enophthalmos in lupus erythematosus profundus. Journal of Neuro-Ophthalmology. 2010;30(1):64–66.
    1. Tuffanelli EL, Dubois DL. Cutaneous manifestations of systemic lupus erythematsus. Archives of Dermatology. 1964;90:377–386.
    1. Gómez-Puerta JA, Levy S, Khamashta MA, Hughes GRV. Periorbital oedema in systemic lupus erythematosus. Lupus. 2003;12(11):866–869.
    1. Gupta T, Beaconsfield M, Rose GE, Verity DH. Discoid lupus erythematosus of the periorbita: clinical dilemmas, diagnostic delays. Eye. 2012;26(4):609–612.
    1. Gunasekera V, Jayaram H, Kashani S, Toma NMG, Olver JM. Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone. Eye. 2008;22(9):1205–1206.
    1. Donzis PB, Insler MS, Buntin DM, Gately LE. Discoid lupus erythematosus involving the eyelids. American Journal of Ophthalmology. 1984;98(1):32–36.
    1. Huey C, Jakobiec FA, Iwamoto T, Kennedy R, Farmer ER, Green R. Discoid lupus erythematosus of the eyelids. Ophthalmology. 1983;90(12):1389–1398.
    1. Acharya N, Pineda R, Uy HS, Foster CS. Discoid lupus erythematosus masquerading as chronic blepharoconjunctivitis. Ophthalmology. 2005;112(5):e19–e23.
    1. Jensen JL, Bergem HO, Gilboe IM, Husby G, Axéll T. Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. Journal of Oral Pathology and Medicine. 1999;28(7):317–322.
    1. Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary sjögren’s syndrome. Arthritis and Rheumatism. 2004;50(3):882–891.
    1. Xu D, Tian X, Zhang W, Zhang X, Liu B, Zhang F. Sjögren’s syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case-control study. Lupus. 2010;19(2):197–200.
    1. Oh JY, Kim MK, Choi HJ, et al. Investingating the relationship between serum interluekin-17 levels and systemic immune-mediated diseases in patients with dry eye syndrome. Korean J Ophthalmol. 2011;25(2):73–76.
    1. Frith P, Burge SM, Millard PR, Wojnarowska F. External ocular finidngs in lupus erythematosus: a clinical and immunopathological study. British Journal of Ophthalmology. 1990;74(3):163–167.
    1. Heiligenhaus A, Dutt JE, Stephen Foster C. Histology and immunopathology of systemic lupus erythematosus affecting the conjunctiva. Eye. 1996;10(4):425–432.
    1. Sitaula R, Shah DN, Singh D. The spectrum of ocular involvement in systemic lupus erythematosus in a teriary eye care center in Nepal. Ocular Immunology and Inflammation. 2011;19(6):422–425.
    1. Read RW, Weiss AH, Sherry DD. Episcleritis in childhood. Ophthalmology. 1999;106(12):2377–2379.
    1. Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Survey of Ophthalmology. 1999;43(5):379–396.
    1. Varga JH, Wolf TC. Bilateral transient keratoendotheliitis associated with systemic lupus erythematosus. Annals of Ophthalmology. 1993;25(6):222–223.
    1. Ruusuvaara P, Setala K. Keratoendotheliitis fugax hereditaria. A clinical and specular microscopic study of a family with dominant inflammatory corneal disease. Acta Ophthalmologica. 1987;65(2):159–169.
    1. Yazici AT, Kara Yuksel K N, Altinkaynak H, Baz O, Bozkurt E, Demirok A. The biomechanical properties of the cornea in patients with systemic lupus erythematosus. Eye. 2011;25(8):1005–1009.
    1. Nemet AY, Vinker S, Bahar I, Kaiserman I. The association of keratoconus with immune disorders. Cornea. 2010;29(11):1261–1264.
    1. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis and Rheumatism. 1988;31(9):1105–1110.
    1. Ushiyama O, Ushiyama K, Koarada S, et al. Retinal disease in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2000;59(9):705–708.
    1. Aiello JS. Ocular findings in lupus erythematosus. American Journal of Ophthalmology. 1952;35(6):837–843.
    1. Aronson AJ, Ordonez NG, Diddie KR, Ernest JT. Immune-complex deposition in the eye in systemic lupus erythematosus. Archives of Internal Medicine. 1979;139(11):1312–1313.
    1. Lanham JG, Barrie T, Kohner EM, Hughes GRV. SLE retinopathy: evaluation by fluorescein angiography. Annals of the Rheumatic Diseases. 1982;41(5):473–478.
    1. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis and Rheumatism. 1988;31(9):1105–1110.
    1. Montehermoso A, Cervera R, Font J, et al. Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 1999;28(5):326–332.
    1. Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clinical and Experimental Ophthalmology. 2004;32(1):87–100.
    1. Jabs DA, Fine SL, Hochberg MC, Newman SA, Heiner GG, Stevens MB. Severe retinal vaso-occlusive disease in systemic lupus erythematosus. Archives of Ophthalmology. 1986;104(4):558–563.
    1. Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erythematosus. Journal of Rheumatology. 1984;11(6):846–850.
    1. Jeon WK, Lee S. Aggravated capillary non-perfusion after intravitreal bevacizumab for macular edema secondary to systempic lupus erythematosus and anti-phospholipid syndrome. Lupus. 2012;21(3):335–337.
    1. Leibovitch I, Goldstein M, Loewenstein A, Barak A. Combined central retinal artery and vein occlusion in a patient with systemic lupus erythematosus. Rheumatology. 2001;40(10):1195–1196.
    1. Durukan AH, Akar Y, Bayraktar Z, Dinc A, Sahin OF. Combined retinal artery and vein occlusion in a patient with asystemic lupus erythematosus and anitphospholipid syndrome. Canadian Journal of Ophthalmology. 2005;40(1):87–89.
    1. Papadaki TG, Zacharopoulos IP, Papaliodis G, Iaccheri B, Fiore T, Foster CS. Plasmapheresis for lupus retinal vasculitis. Archives of Ophthalmology. 2006;124(11):1654–1656.
    1. Damato E, Chilov M, Lee R, Singh A, Harper S, Dick A. Plasma exchange and rituximab in the management of acute retinal vaso-occlusive disease in systemic lupus erythematosus. Ocular Immunology and Inflammation. 2011;19(5):379–381.
    1. Baglio V, Gharbiya M, Balacco-Gabrieli C, et al. Choroidopathy in patients with systemic lupus erythematosus with or without nephropathy. Journal of Nephrology. 2011;24(4):522–529.
    1. Hannouche D, Korobelnik JF, Cochereau I, et al. Systemic lupus erythematosus with choroidopathy and serous retinal detachment. International Ophthalmology. 1995;19(2):125–127.
    1. Schwartz MM, Roberts JL. Membranous and vascular choroidopathy: two patterns of immune deposits in systemic lupus erythematosus. Clinical Immunology and Immunopathology. 1983;29(3):369–380.
    1. Matsuo T, Nakayama T, Koyama T, Matsuo N. Multifocal pigment epithelial damages with serous retinal detachment in systemic lupus erythematosus. Ophthalmologica. 1987;195(2):97–102.
    1. Gharbiya M, Bozzoni-Pantaleoni F, Augello F, Balacco-Gabrieli C. Indocyanine green angiographic findings in systemic lupus erythematosus choroidopathy. American Journal of Ophthalmology. 2002;134(2):286–290.
    1. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropyschiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relations to other features of the disease. Medicine. 1976;55(4):323–329.
    1. Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmologica. 2009;87(2):204–210.
    1. Optic Neuritis Study Group. The clinical profile of acute optic neuritis: experience of the optic neuritis treatment trial. Archives of Ophthalmology. 1991;109(12):1673–1678.
    1. Smith CH, et al. Optic neuritis. In: Miller NR, Newman NJ, editors. Walsh and Hoyt’s Clinical Neuro-Ophthalmology. 6th edition. Vol. 1. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2005. pp. 293–347.
    1. Siatkowski RM, Scott IU, Verm AM, et al. Optic neuropathy and chiasmopathy in the diagnosis of systemic lupus erythematosus. Journal of Neuro-Ophthalmology. 2001;21(3):193–198.
    1. Sergio P, Mariana B, Alberto O, et al. Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature. Clinical Rheumatology. 2010;29(11):1335–1338.
    1. Kenik JG, Krohn K, Kelly RB, Bierman M, Hammeke MD, Hurley JA. Transverse myelitis and optic neuritis in systemic lupus erythematosus: a case report with magnetic resonance imaging findings. Arthritis and Rhumatisim. 1987;30(8):947–950.
    1. Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nature Clinical Practice Rheumatology. 2008;4(7):381–386.
    1. Jarius S, Jacobi C, de Seze J, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal. 2011;17(9):1067–1073.
    1. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology. 2006;59(3):566–569.
    1. Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clinical Rheumatology. 1999;18(2):124–131.
    1. Frigui M, Frikha F, Sellemi D, Chouayakh F, Feki J, Bahloul Z. Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. Lupus. 2011;20(11):1214–1218.
    1. Myers TD, Smith JR, Wertheim MS, Egan RA, Shults WT, Rosenbaum JT. Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease. British Journal of Ophthalmology. 2004;88(5):673–680.
    1. Rosenbaum JT, Simpson J, Neuwelt CM. Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. British Journal of Ophthalmology. 1997;81(2):130–132.
    1. Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Archives of Neurology. 1995;52(12):1145–1149.
    1. Galindo M, Pablos JL, Gomez-Reino JJ. Internuclear ophthalmoplegia in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 1998;28(3):179–186.
    1. Cogen MS, Kline LB, Duvall ER. Bilateral internuclear ophthalmoplegia in systemic lupus erythematosus. Journal of Clinical Neuro-Ophthalmology. 1987;7(2):69–73.
    1. Meyer MW, Wild JH. Letter: unilateral internuclear ophthalmoplegia in systemic lupus erythematosus. Archives of Neurology. 1975;32(7):p. 486.
    1. Barahona-Hernando R, Rios-Blanco JJ, Mendez-Meson I, et al. Idiopathic intracranial hypertension and systemic lupus erythematosus: a case report and review of the literature. Lupus. 2009;18(12):1121–1123.
    1. Lo GC, Tsokos MS. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Annals of the New York Academy of Sciences. 2012;1247:138–152.
    1. Goodwin JS, Atluru D, Sierakowski S, Lianos EA. Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4. Journal of Clinical Investigation. 1986;77(4):1244–1250.
    1. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000;55(7):603–613.
    1. Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–298.
    1. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–422.
    1. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Archives of Ophthalmology. 2011;129(1):30–39.
    1. Pinto LF, Velaásquez CJ, Prieto C, Mestra L, Forero E, Marquez JD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20(11):1219–1226.
    1. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism. 2010;62(8):2458–2466.
    1. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmunity Reviews. 2011;11(1):35–39.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren